Screening Colonoscopy With Polypectomy: Preventive Coding and Cost Sharing

Diagnosis sequencing is right; the preventive flagging is inconsistent.

• Diagnosis: Z12.11 (encounter for screening for malignant neoplasm of colon) stays first even though a polyp was found, because screening was the reason for the encounter; K63.5 (polyp of colon) is secondary. That part is correct.
• Professional claim: modifier 33 (preventive service) tells the payer the service was preventive in intent. Whether a payer wants 33 on the therapeutic code after a polypectomy varies; the plan's own policy must be checked. Keep it if the plan's policy supports it.
• ASC claim: 45385 with no screening modifier and no preventive flag is the likelier processing error. The facility claim should carry the same preventive identification the plan requires.
• Benefit argument: federal guidance on ACA preventive services has clarified that plans must cover a screening colonoscopy without cost sharing even when a polyp is removed during the same screening procedure. Combined with the plan's own benefit summary language, the practice has a strong reprocessing request.

Action: request reprocessing of both claims as preventive, citing the benefit summary and the screening-first diagnosis, and attach the procedure note showing the intent was screening.

Escalate in writing, and hold the balance.

• First level: a formal plan-level appeal/grievance with the benefit summary, the provider agreement language, the procedure note, and the diagnosis sequencing. Ask specifically for a benefit determination (is this a preventive service under the plan?) rather than a clinical review - the dispute is contractual, not medical.
• Second level: request an external review (state or ERISA-based, depending on whether the plan is fully insured or self-funded) after exhausting internal appeals. For a fully insured plan, a state insurance department complaint is often the fastest lever; for a self-funded ERISA plan, follow the plan document's appeal and external review procedures.
• The $940: place the account on hold with a note that a payer dispute is active. Do not bill, do not send statements that threaten collections, and do not refer to an agency. If the appeal fails, re-evaluate patient responsibility against the plan document before billing.
• Communication: call the patient, explain the coding and the appeal, and give a date for follow-up. A complaint to the insurance commissioner from a surprised patient is harder to manage than a phone call now.

Medicare uses a different modifier and different liability rules.

• Coding: report 45385 with modifier PT (colorectal cancer screening test converted to a diagnostic test or other procedure), with Z12.11 first and K63.5 secondary. Modifier 33 is a commercial/preventive flag, not the Medicare approach here.
• Cost sharing: Medicare's screening benefit waives the deductible, but once a polyp is removed the procedure becomes therapeutic and the beneficiary generally owes the applicable coinsurance. The PT modifier lets the MAC identify that the case began as a screening so the claim is processed correctly.
• Patient notice: an ABN is not needed to collect the standard coinsurance - that is statutory cost sharing, not a denial of coverage. An ABN would be needed only to bill for a service Medicare considers not reasonable and necessary.
• Practical contrast: the commercial patient's argument is contractual (the plan promised a free screening); the Medicare patient's argument is statutory (screening is free, but therapeutic conversion changes the cost-sharing calculation). The same clinical event produces different patient balances, so the front desk script must differ by payer.